


AF 1617



CERTIFICATE OF MAILING 37 C.F.R. § 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
April 29, 2004 Date	 Shelley P.M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Philip E. Thorpe Sophia Ran and
Rolf A. Brekken (As Amended)

Serial No.: 09/351,149

Filed: July 12, 1999

For: CANCER TREATMENT KITS
COMPRISING THERAPEUTIC
CONJUGATES THAT BIND TO
AMINOPHOSPHOLIPIDS

Group Art Unit: 1617

Examiner: Sharareh, S.

Atty. Dkt. No.: 3999.002383

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22131-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A Final Official Action has been received in the present application. However, this Supplemental Information Disclosure Statement is being submitted in an abundance of caution and should be enterable under 37 C.F.R. § 1.97(d) in light of the following information. In the alternative, for completeness and to most fully comply with the duty of disclosure, the enclosed document should be placed in the file in accordance with 37 C.F.R. § 1.97(i).

In accordance with 37 C.F.R. § 1.97(e)(2), it is hereby certified that the documents listed in the accompanying Form PTO-1449 were not cited in a communication from a foreign patent office in a counterpart foreign application. The listed PCT and U.S. patent applications by Brams were identified in searches of patent databases conducted by the licensee and the undersigned representative on about April 01, 2004. The other listed documents were cited on the international search report for the Brams PCT application, and were not of record in the present application. This Supplemental Information Disclosure Statement is submitted within three months of the April 01, 2004 searches and the listed documents could not have been submitted before conducting the searches and reviewing the Brams PCT application search report.

No fees should be due in connection with the filing of this Supplemental Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.97(d) and 1.17(p) be due, the Examiner should contact the undersigned representative to discuss deduction from Williams, Morgan & Amerson Deposit Account No. 50-0786/3999.002383.

Respectfully submitted,
Williams, Morgan & Amerson, P.C.
Customer No. 23720



Shelley P.M. Fussey, Ph.D.
Reg. No. 39,458
Agent for Applicants

10333 Richmond, Suite 1100
Houston, Texas, 77042
(713) 934-4079

Date: April 29, 2004



Form PTO-1449 (modified)		Atty. Docket No. 3999.002383	Serial No. 09/351,149
Office of Patents and Publications for Applicant's		Applicant Thorpe, Ran and Brekken	
INFORMATION DISCLOSURE STATEMENT		Filing Date: July 12, 1999	Group: 1617
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A35	2002/0025319 A1	Feb. 28, 2002	Brams	424	178.1	
	A36	6,020,153	Feb. 1, 2000	Hardman <i>et al.</i>	435	69.1	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B28	WO 01/68709	Sept. 20, 2001	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C103	Adler <i>et al.</i> , "Monoclonal Antiphosphatidylserine Antibody Inhibits Intercellular Fusion of the Choriocarcinoma Line, JAR", <i>Biology of Reproduction</i> , 53:905-910, 1995.
	C104	Bakimer <i>et al.</i> , "Antiphospholipid Syndrome and the Idiotypic Network," <i>Lupus</i> , 4(3):204-208, 1995 (Abstract only).
	C105	Fishman <i>et al.</i> , "Vitiligo Autoantibodies are Effective Against Melanoma," <i>Cancer</i> , 72:2365-2369, 1993.
	C106	Hosomi <i>et al.</i> , "Simple Purification Method of the Antiphospholipid Antibody from Normal Human Plasma," <i>Exp. Clin. Immunogenet.</i> , 14:281-285, 1997.
	C107	Miyazawa <i>et al.</i> , "Monoclonal Antibody Analysis of Phosphatidylserine and Protein Kinase C Localizations in Developing Rat Cerebellum," <i>J. Neurochem.</i> , 59:1547-1554, 1992.
	C108	Reza <i>et al.</i> , "Anti-Idiotypic Monoclonal Antibody Recognizes a Consensus Recognition Site for Phosphatidylserine in Phosphatidylserine-Specific Monoclonal Antibody and Protein Kinase C," <i>FEBS Lett.</i> , 339:229-233, 1994.
	C109	International Search Report for PCT/US01/07895, mailed June 06, 2001.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.